Navigation Links
Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
Date:12/1/2009

SCHAUMBURG, Ill., Dec. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of two antibiotics: cefoxitin for injection, USP and ceftriaxone for injection, USP. Both are antibiotics of the cephalosporin family and have activity against gram-positive and gram-negative bacteria. Sagent will launch ceftriaxone in a 10 g vial in December to complement the four vial sizes launched by Sagent in July 2008. Cefoxitin 1 g and 2 g vials are now available. According to 2008 IMS data, the approximate U.S. market was $19 million for cefoxitin for injection and $113 million for the ceftriaxone for injection product line.

"We are pleased to add two presentations of cefoxitin, and the ceftriaxone line extension, which provides an important ceftriaxone pharmacy bulk package option for customers, to our portfolio of antibiotics," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "Even as our antibiotics portfolio, in particular, continues to grow, we remain focused on offering our customers a broad array of specialty injectables, all of which are latex free and feature our signature packaging enhancements."

About Cefoxitin for Injection, USP

Cefoxitin for injection, USP is indicated for the treatment of serious infections caused by susceptible strains of designated microorganisms in these diseases: lower respiratory tract infections, including pneumonia and lung abscess; urinary tract infections; intra-abdominal infections, including peritonitis and intra-abdominal abscess; gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease; septicemia; bone and joint infections; and skin and skin structure infections.

About Ceftriaxone for Injection, USP

Ceftriaxone for injection, USP is a broad spectrum cephalosporin antibiotic used to treat a variety of infections. Ceftriaxone for injection is indicated for infections of the lower respiratory tract, urinary tract, skin and skin-structure, intra-abdomen, and bones and joints, as well as acute otitis media, uncomplicated gonorrhea, pelvic inflammatory disease, bacterial septicemia and meningitis. Ceftriaxone may also reduce the incidence of postoperative infections is used as a surgical prophylaxis preoperatively.

Package inserts for cefoxitin for injection, USP and ceftriaxone for injection, USP are available at www.SagentPharma.com and contain detailed information about the indications, complete side effect profiles, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.

SOURCE Sagent Pharmaceuticals, Inc.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
2. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
3. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
4. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
Breaking Medicine News(10 mins):